Xenon Pharmaceuticals
XENE
25 hedge funds and large institutions have $46.5M invested in Xenon Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
3% more capital invested
Capital invested by funds: $45.2M → $46.5M (+$1.25M)
0% more funds holding
Funds holding: 25 → 25 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.27M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$771K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$623K |
| 4 |
Renaissance Technologies
New York
|
+$159K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$22.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$241K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$86K |
| 3 |
IPC
Invesco Private Capital
New York
|
-$70.9K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$36.3K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$18K |
XENE Hedge Fund Activity: Q4 2015 in Review
25 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q4 2015, worth a combined $46.5M — up 2.8% from $45.2M a quarter earlier.
Fund positioning in XENE was balanced in Q4 2015: 3 funds opened new positions, 3 closed out, 7 added to existing stakes and 4 trimmed.
The largest buyer was Opaleye Management, adding an estimated $1.27M. The largest seller was GSA Capital Partners, cutting an estimated $241K.
- 25 institutional investors held Xenon Pharmaceuticals (XENE) as of Q4 2015, unchanged from Q3 2015.
- Funds reported $46.5M of Xenon Pharmaceuticals stock for Q4 2015, up 2.8% quarter-over-quarter.
- 3 funds opened new Xenon Pharmaceuticals positions in Q4 2015 and 3 closed out, a net change of 0 holders.
- The largest Xenon Pharmaceuticals buyer in Q4 2015 was Opaleye Management, an estimated $1.27M added.
- The largest Xenon Pharmaceuticals seller in Q4 2015 was GSA Capital Partners, an estimated $241K sold.
Based on aggregated 13F filings for Q4 2015.